Institute of Molecular Genetics, Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic.
Transpl Immunol. 2011 Apr 15;24(3):189-94. doi: 10.1016/j.trim.2010.11.005. Epub 2010 Nov 28.
Limbal transplantation or limbal stem cell (LSC) transfer represents the only way to treat severe ocular surface damage or LSC deficiency. However, limbal allografts are promptly rejected in spite of extensive immunosuppressive therapy. To characterize immune response after limbal transplantation, we established an experimental model of limbal transplantation in the mouse. Syngeneic, allogeneic and xenogeneic (rat) limbal grafts were grafted orthotopically in BALB/c mice and graft survival was evaluated. The presence of graft donor cells and the expression of IL-2, IL-4, IL-10, IFN-γ and inducible nitric oxide synthase (iNOS) mRNA in the grafts were detected by real-time PCR. While syngeneic grafts survived permanently, allografts were rejected in 9.0±1.8 days and xenografts in 6.5±1.1 days. The manifestation of clinical symptoms of rejection correlated with the disappearance of donor cells in the graft and in the recipient cornea. Intragraft expression of iNOS mRNA and distinct expression patterns of Th1 (IL-2, IFN-γ) and Th2 (IL-4, IL-10) cytokines were detected during rejection of limbal allografts and xenografts. The limbal graft rejection was prevented with anti-CD4, but not anti-CD8 monoclonal antibody therapy. The results indicate that limbal grafts do not enjoy immune privilege of the eye and are promptly rejected by Th1 (allografts) or by a combined Th1 and Th2 (xenografts) type of immune response involving CD4+ cells and iNOS expression. Targeting this pathway may be an effective way to prevent and treat limbal graft rejection.
角膜缘移植或角膜缘干细胞(LSC)转移是治疗严重眼表损伤或 LSC 缺乏的唯一方法。然而,尽管进行了广泛的免疫抑制治疗,角膜缘同种异体移植物仍会迅速被排斥。为了描述角膜缘移植后的免疫反应,我们在小鼠中建立了角膜缘移植的实验模型。将同基因、同种异体和异种(大鼠)角膜缘移植物原位移植到 BALB/c 小鼠中,并评估移植物的存活情况。通过实时 PCR 检测移植物中供体细胞的存在以及 IL-2、IL-4、IL-10、IFN-γ 和诱导型一氧化氮合酶(iNOS)mRNA 的表达。虽然同基因移植物永久存活,但同种异体移植物在 9.0±1.8 天内被排斥,异种移植物在 6.5±1.1 天内被排斥。排斥的临床表现与移植物和受体角膜中供体细胞的消失相关。在角膜缘同种异体和异种移植物排斥过程中,检测到 iNOS mRNA 的内移植物表达以及 Th1(IL-2、IFN-γ)和 Th2(IL-4、IL-10)细胞因子的明显表达模式。用抗 CD4 单克隆抗体而非抗 CD8 单克隆抗体治疗可预防角膜缘移植物排斥。结果表明,角膜缘移植物不享有眼部的免疫特权,并且会迅速被 Th1(同种异体)或涉及 CD4+细胞和 iNOS 表达的 Th1 和 Th2(异种)混合免疫反应所排斥。靶向该途径可能是预防和治疗角膜缘移植物排斥的有效方法。